Amid rising investor concerns over managerial practices at Sun Pharma, the company has asked Indian securities regulators to investigate the media for reporting on whistleblower allegations that have raised questions about corporate governance.

In a letter sent last Thursday to the Securities and Exchange Board of India, the drug maker, one of India’s largest pharmaceutical companies, complained that certain individuals or firms adopted “unfair trade practices” and that “it is evident from the fact that shareholders value has been drastically eroded within a short span of time due to unsubstantiated complaints or allegations against the company and mala fide campaign launched by certain media.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy